A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label, international, multi-center, Phase 3 study in which patients are
randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.
Phase:
Phase 3
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.